Built in the US to deliver for patients—today and for the long term

We’re discovering and manufacturing our innovative medicines right here to help more patients across the United States.

For the first time in our history, Novartis will be able to deliver end-to-end US manufacturing of our key innovative medicines for patients in the US. We’re breaking new ground nationwide, researching new solutions, and building a resilient, future-ready supply chain to deliver meaningful impact for people and society. 

Our Coast-to-Coast Network

Manufacturing sites across US map, grey scale

Learn More About Our US Sites

From New Jersey to California, every Novartis site is a hub of innovation, talent, and impact built to unlock new treatments, advance research, and engineer breakthrough medicines. Our coast-to-coast network of research and development and manufacturing sites drives our $23B investment in innovation, bringing therapies closer to patients and powering progress in communities across the United States. Click a site description below to learn more about that location.

Biomedical Research organization in Cambridge, Massachusetts

Cambridge, MA

This Biomedical Research organization, established in 2003, is dedicated to scientific innovation and drug discovery.
Novartis Radioligand Therapy Production Carlsbad California

Carlsbad, CA

Our third US radioligand therapy manufacturing site opened in 2025 and serves patients across the western US, Alaska and Hawaii.
Scientist working in a laboratory with test tubes and scientific equipment

Denton, TX

Expected to become fully operational in 2028, our fifth US radioligand manufacturing site will serve patients in the southern US.
Novartis Gene Therapy Production Durham, North Carolina

Durham, NC (14TW)

Expected to be operational in 2028, the site will house two new facilities for manufacturing biologics and sterile packaging.
Novartis Gene Therapy Production Durham North Carolina

Durham, NC (TriCenter)

The site produces innovative gene therapies and is expanding to support sterile filling of biologics into syringes and vials. 
Novartis Radioligand Therapy Production Indianapolis Indiana

Indianapolis, IN

Our second US radioligand therapy manufacturing site opened in 2024. Expansion of the site is ongoing.
Novartis Radioligand Therapy Production Millburn New Jersey

Millburn, NJ

Our first US radioligand therapy manufacturing site opened in 2023. Its on-site production capabilities continue to expand.
Morrisville, North Carolina

Morrisville, NC

Two new facilities for production and packaging of small molecule medicines, and active pharmaceutical ingredient manufacturing.
Novartis Cell Therapy Production Morris Plains New Jersey

Morris Plains, NJ

Since 2015, the site has specialized in the production of groundbreaking cell therapies.
Novartis Biomedical Research Center in San Diego, California

San Diego, CA

In 2026, we broke ground on a new global Biomedical Research center designed to accelerate drug discovery.
radioligand therapy manufacturing facility in Winter Park, Florida

Winter Park, FL

Expected to open in 2029, our fourth US radioligand manufacturing site will optimize delivery for patients across the southeastern US.

Investing in America's Health: Learn About Our Commitment

Watch our investment in America come to life: See how we are creating end-to-end manufacturing to produce all of our key medicines, for the United States, in the United States. 

 

Our US Investment, By the Numbers

$23B
Investment

Over five years to expand our US-based infrastructure and support more patients across the United States

7
New Facilities

Across our 11 US manufacturing and R&D sites

~1000
New Jobs

at Novartis and approximately 4,000 additional US jobs

Our Stories

Learn about the people who make our medicine, the communities we work in, and how we scale innovation to reach more patients.
Portrait of Thierry Diagana, California Site Head for Novartis Biomedical Research, wearing black sweater and white collared shirt

Novartis in San Diego: A Quarter Century of R&D Innovation

A look back at a legacy of biomedical research breakthroughs that trace their roots to our San Diego site.
neural web

What's next in Neuroscience drug discovery: A conversation with Genetic Medicine head Bryan Laffitte

A Q&A with Bryan Laffitte, who leads a Novartis team that’s using the tools of genetic medicine to innovate new therapies for neuromuscular and neurodegenerative conditions.
A Novartis employee and Veteran, Matt Baca, featured during his time in the military.

How This Former Army Officer Helps Deliver Cancer Treatments to Patients, Through Hurricanes and Beyond

Radioligand therapies harness the power of radioisotopes to target cancer with precision. For Matt Baca, delivering a dose in a three-to-five-day window is all in a day’s work.

Latest US Investment News

May 07, 2026

  • Media Release

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Apr 30, 2026

  • Media Release

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

Feb 25, 2026

  • Media Release

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
View More
Scientist working in lab in East Hanover

Explore Opportunities at Novartis

From science roles to manufacturing to business, find the right role at Novartis in the US and join us as we work to reimagine medicine.

Learn more about all career opportunities at Novartis